PACB250516P4000
- 2.87
- 0.000.00%
Pacific Biosciences of California Newsroom
PacBio Announces Strategic Collaboration To Implement PacBio HiFi Whole Genome Sequencing As Part Of Newborn Screening Research Program
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
Earnings Preview: PACB to Report Financial Results Post-market on May 08
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing
Express News | Pacbio Announces Plans to Improve Methylation Detection in Hifi Chemistry
PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry
Here's an Easy Way to Earn Income for Doing Almost Nothing -- Barrons.com
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner
Express News | Davos Alzheimer’s Collaborative Selects Pacbio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa
Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa
Bernstein Keeps Their Buy Rating on Pacific Biosciences (PACB)
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
Positive Week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Investors Who Lost 57% Over the Past Year
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $2
Pacific Biosciences Price Target Maintained With a $3.00/Share by Canaccord Genuity
Pacific Biosciences Is Maintained at Buy by Canaccord Genuity
Pacific Biosciences Analyst Ratings